Serum Spexin Level Is Negatively Associated With Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes
Journal of Diabetes Research · 2024
DOI: 10.1155/2024/4538199 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Research, 2024. Verfasst von Ying Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism Huashan Hospital Fudan University, Shanghai 200040, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Neuropathies, Diabetes Mellitus, Experimental, Peptide Hormones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Spexin is a novel peptide hormone and has shown antinociceptive effects in experimental mice. This study is aimed at evaluating the association of serum spexin level with diabetic peripheral neuropathy (DPN) and related pain in a Chinese population.
Methods
We enrolled 167 type 2 diabetes mellitus (T2DM) including 56 patients without DPN (non‐DPN), 67 painless DPN, and 44 painful DPN. Serum spexin was measured using ELISA. Logistic regression models were performed to analyze the independent effects of spexin on prevalence of DPN and painful DPN. In streptozotocin (STZ)‐induced diabetic mice, mechanical pain threshold was measured using electronic von Frey aesthesiometer. Human peripheral blood mononuclear cells (PBMCs) were isolated and further stimulated with lipopolysaccharide without or with spexin. The gene expression was assayed by qPCR.
Results
Compared with non‐DPN, serum spexin level decreased in painless DPN and further decreased in painful DPN. The odds of DPN was associated with low spexin level in T2DM, which was similar by age, sex, BMI, and diabetes duration, but attenuated in smokers. The odds of having pain was associated with decreased spexin level in DPN, which was similar by age, sex, smoking status, and diabetes duration, but attenuated in normal weight. Furthermore, we observed that mechanical pain threshold increased in spexin‐treated diabetic mice. We also found that lipopolysaccharide treatment increased the mRNA level of TNF‐ α , IL‐6, and MCP‐1 in human PBMCs, while spexin treatment prevented this increase.
Conclusions
These results suggested that spexin might serve as a protective factor for diabetes against neuropathology and pain‐related pathogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolism Huashan Hospital Fudan University, Shanghai 200040, China.
- Institute of Endocrinology and Diabetes Fudan University, Shanghai 200040, China.
ORCID-Profile: Ying Liu, Yunzhi Ni, Jiarong Dai, Quanya Sun, Yehong Yang, Rui Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Wu, D., Zheng, H., Ni, Y., Zhu, L., Jiang, Y., Dai, J., Sun, Q., Zhao, Y., Zhang, Q., Yang, Y., & Liu, R. (2024). Serum Spexin Level Is Negatively Associated With Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes. Journal of Diabetes Research. https://doi.org/10.1155/2024/4538199
Vancouver
Liu Y, Wu D, Zheng H, Ni Y, Zhu L, Jiang Y, et al. Serum Spexin Level Is Negatively Associated With Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes. Journal of Diabetes Research. 2024. doi:10.1155/2024/4538199
BibTeX
@article{Liu2024,
author = {Liu, Ying and Wu, Di and Zheng, Hangping and Ni, Yunzhi and Zhu, Lu and Jiang, Yaojing and Dai, Jiarong and Sun, Quanya and Zhao, Ying and Zhang, Qi and Yang, Yehong and Liu, Rui},
title = {Serum Spexin Level Is Negatively Associated With Peripheral Neuropathy and Sensory Pain in Type 2 Diabetes},
journal = {Journal of Diabetes Research},
year = {2024},
doi = {10.1155/2024/4538199}
}
EUVIMED